|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromogranin A (CgA), which is a major protein in adrenal chromaffin cells and adrenergic neurons, is a clinically relevant endocrine and neuroendocrine tumor marker including pheochromocytomas, neuroblastomas, and related neurogenic tumors.
|
31682468 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For neoplastic disease (NSCLC, SCC), CgA was elevated in 11-16%.
|
30995665 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers.
|
31207989 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated CgA (p = 0.004), Ki67% (p < 0.001), tumor grade (p < 0.001) and stage of disease (p = 0.036) were associated with disease-specific survival.
|
30366884 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we have applied RNA in situ hybridization and immunohistochemistry assays to measure the expressions of SRRM4, NEPC markers (SYP, CD56, and CHGA), and adenocarcinoma (AdPC) markers (AR, PSA) in a series of tissue microarrays constructed from castrate-resistant prostate tumors, treatment-naïve tumors collected from radical prostatectomy, and tumors treated with neoadjuvant hormonal therapy (NHT) for 0-12 months.
|
30155992 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prox1 also showed significant difference in expression according to chromogranin A and calcitonin immunohistochemical expression, with higher Prox1 expression in tumors with stronger chromogranin A or calcitonin staining.
|
31001799 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIGNIFICANCE: This work reveals that the interaction between fragmented chromogranin A and neuropilin-1 is required for tumor growth and represents a novel potential therapeutic target.
|
30796053 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No significant correlation between CgA and tumor diameter was found (P = 0.057).
|
30470614 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No association was observed between serum CgA levels and tumour grade (G1, G2 and G3), but serum CgA levels differed significantly between patients with GEP-NENs of different origins (P<0.05).
|
30675205 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
|
30325865 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the nomogram was not universally applicable as even at our specialty center, variables such as chromogranin A and urinary 5-hydroxyindoleacetic acid are not routinely collected, whereas others, like tumor grade, do not reflect the most recently updated classifications.
|
30946234 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Age (p=0.131), gender (p=0.051), chromogranin A level (p=0.104), Ki-67 index (p=0.550), tumor size (p=0.623), and primary tumor area (p=0.154) did not influence the overall survival.
|
31625933 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, we found that compound (Apc<sup>Min/+</sup>; Gfi1<sup>F/F</sup>; CDX2-cre) mice develop larger adenomas, invasive carcinoma, as well as hyperplastic lesions expressing the neuroendocrine marker chromogranin A, a feature that has not been previously described in APC-mutant tumors in mice.
|
30606770 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The neoplasm was positive for calcitonin and chromogranin A and negative for thyroglobulin.
|
30574858 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Genomic profiling of NET was analyzed along with nongenomic biomarker data on tumor grade and circulating chromogranin A (CgA) and neuron specific enolase (NSE) levels from these patients enrolled in clinical trials.
|
30667365 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In both PT and MTS lower SST2A and CgA expression levels were found in tumors originating from the appendix or colon, compared to tumors from other origins.
|
30867449 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no correlation between the expression and the chromogranin A levels, the grades or the hormonal activity/inactivity of the given neoplasms.
|
29862475 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cox regression analysis identified four variables for inclusion in the risk score: CgA > 5x ULN (HR 4.3, p = 0.01), tumor grade 2/3 (HR 3.7, p = 0.01), resection for recurrent disease (HR 6.2, p < 0.01), and tumor size > 4 cm (HR 4.5, p = 0.1).Each variable was assigned 1 point.
|
30659439 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Positive chromogranin A staining of the tumor cells confirmed a diagnosis of pheochromocytoma.
|
30078826 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In patients with NENs of the pancreas, CgA concentration was correlated with tumour grade and Ki67.
|
29724794 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Older age greater than 50 years (P = .027), higher levels of Chromogranin A (CgA) (P = .034), first-line treatment with surgery (P = .005), ki67 over 10% (P = .037), and tumor stage (P = .036) but not tumor grade (P = .22), were significantly associated with survival.
|
28026127 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, its accuracy as a tumor biomarker is relatively low because plasma CgA can increase also in patients with other diseases or in subjects treated with proton-pump inhibitors (PPIs), a class of widely-used drugs.
|
29723285 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In NF-pNETs, CgA correlated with the WHO tumor grade (WHO G1 vs G2, <i>P</i> < 0.05); the linear regression relationships were found between the tumor burdens (both in pancreas and liver) and CgA concentration (<i>P</i> < 0.001); changes in CgA and NSE concentrations also reflect treatment response (<i>P</i> < 0.001).
|
29191920 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
|
29633144 |
2018 |